Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03077828 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 43 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03226249 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05883709 | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | unknown | — | 15 | Zhao WeiliOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2023 | clinicaltrials |
| NCT05771883 | A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide | unknown | Phase 1 / Phase 2 | 102 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05860179 | Examination of Trends in Multiple Myeloma Trial Patient Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 23, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05271682 | A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma | unknown | Phase 1 | 40 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05859932 | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05858203 | Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment(AATF/Che-1) | unknown | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05855460 | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | unknown | — | 20 | Cairo UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05840289 | A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma(FRILLY) | unknown | — | 94 | University Hospital, GenevaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05832125 | Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia(ALLTARGETOBS) | unknown | — | 80 | Versailles HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04139252 | A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients(HO902DLBCL) | unknown | — | 250 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04957693 | Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period | unknown | N/A | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05823701 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | unknown | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05749133 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | XuYanOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05821192 | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. | unknown | N/A | 34 | Ou Bai, MD/PHDOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05822037 | CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 6 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04861480 | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05490953 | Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma | unknown | Phase 4 | 30 | University of GuadalajaraOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05438394 | Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM | unknown | Phase 1 | 24 | Peking University People's HospitalOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05308225 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 72 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05802992 | The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | unknown | Phase 3 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | unknown | Phase 3 | 116 | Air Force Military Medical University, ChinaOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | unknown | — | 150 | Maastricht University Medical CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05772728 | Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | unknown | N/A | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 48 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04941937 | Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM | unknown | Phase 2 | 90 | Juan DuOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05744037 | Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells | unknown | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05739188 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2023source: clinicaltrials